The European Medicines Agency’s (EMA)) human medicines committee (CHMP) has recommended seven novel medicines for approval at ...

Net product revenues have likely increased in the first quarter, driven by a rise in Cabometyx sales volumes and average net ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Vertex Pharmaceuticals (VRTX) closed at $492.47 in the latest trading session, marking a +0.01% move from the prior day.

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell ...

Analysts are piling on the praise for Vertex Pharmaceuticals, reaffirming bullish ratings even as the stock slightly fumbles ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Notably, EPS and sales expectations have primarily remained unchanged over recent months, with the Zacks Consensus EPS estimate of $0.62 suggesting 44% growth year-over-year. Sales growth is also ...

The biopharmaceutical industry saw a strong start to 2025, despite ongoing uncertainty around the potential impact of US ...

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company ...